Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mortality in sickle cell patients on hydroxyurea therapy.
Bakanay SM, Dainer E, Clair B, Adekile A, Daitch L, Wells L, Holley L, Smith D, Kutlar A. Bakanay SM, et al. Among authors: daitch l. Blood. 2005 Jan 15;105(2):545-7. doi: 10.1182/blood-2004-01-0322. Epub 2004 Sep 28. Blood. 2005. PMID: 15454485 Free article.
Sickle cell disease telemedicine network for rural outreach.
Woods KF, Johnson JA, Kutlar A, Daitch L, Stachura ME. Woods KF, et al. Among authors: daitch l. J Telemed Telecare. 2000;6(5):285-90. doi: 10.1258/1357633001935923. J Telemed Telecare. 2000. PMID: 11070590
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. Steinberg MH, et al. Am J Hematol. 2010 Jun;85(6):403-8. doi: 10.1002/ajh.21699. Am J Hematol. 2010. PMID: 20513116 Free PMC article. Clinical Trial.
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW; ICA-17043-10 Study Investigators. Ataga KI, et al. Br J Haematol. 2011 Apr;153(1):92-104. doi: 10.1111/j.1365-2141.2010.08520.x. Epub 2011 Feb 17. Br J Haematol. 2011. PMID: 21323872 Free article. Clinical Trial.